Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year
Participants must be using Continuous Glucose Monitoring (CGM) with total CGM use ≥ 2 months in the prior 6 months
Participants must have been on the same type of short acting insulin (Humalog U-100, Novolog, Admelog, or Apidra) for at least 30 days prior to screening
Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening
You may not be if
Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening
Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening
Participants must not be taking certain diabetes medications that are not allowed for study participation
Clareo Health | A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
